Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028

1.1 List of Tables
1.2 List of Figures

2.1 Sales for COPD by Country, 2018-2028
2.2 GSK continues to dominate the COPD market in 2028
2.3 Despite the Variety of Available Therapies, COPD Remains a Market with High Unmet Need
2.4 Treatments that Reverse the Progression of COPD Remain Elusive
2.5 Pipeline COPD Treatment to Target a Niche Population
2.6 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for COPD (2018 - 2028)
5.5.1 Total Prevalent Cases of COPD
5.5.2 Sex-Specific Total Prevalent Cases of COPD
5.5.3 Age-Specific Total Prevalent Cases of COPD
5.5.4 Diagnosed Prevalent Cases of COPD
5.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
5.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
5.5.7 Diagnosed Prevalent Cases of COPD by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan

7.1 Overview

8.1 Overview
8.2 Disease-Modifying Treatments to Reverse the Progression of COPD
8.3 Identification of Biomarkers that Predict Efficacy
8.4 Observance of GOLD Guidelines Among General Practitioners
8.5 Improved Clinical Trial Design
8.6 Earlier Diagnosis and Recognition of Symptoms

9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 IL-4/IL-5 inhibitors
9.2.2 IL-33 inhibitors
9.2.3 PDE inhibitors
9.2.4 CFTR modulators

Table 1: COPD: Key Metrics in the 7MM
Table 2: GOLD Criteria for the Classification of COPD, 2018
Table 3: Symptoms of COPD
Table 4: Modified mMRC Dyspnea Scale
Table 5: Risk Factors and Comorbidities for COPD
Table 6: Treatment Guidelines for COPD
Table 7: Country Profile - US, 2018
Table 8: Region Profile - 5EU, 2018
Table 9: Country Profile - Japan, 2018
Table 10: Leading Treatments for COPD, 2018
Table 11: Comparison of Therapeutic Classes in Development for COPD, 2018-2028
Table 12: AstraZeneca’s COPD Portfolio Assessment, 2019
Table 13: Chiesi’s COPD Portfolio Assessment, 2019
Table 14: GSK’s COPD Portfolio Assessment, 2019
Table 15: Novartis’ COPD Portfolio Assessment, 2019
Table 16: Sunovion’s COPD Portfolio Assessment, 2019
Table 17: Sunovion’s COPD Portfolio Assessment, 2019
Table 18: Theravance’s COPD Portfolio Assessment, 2019
Table 19: COPD Market - Global Drivers and Barriers, 2018-2028
Table 20: Key Events Impacting Sales for COPD in the US, 2018-2028
Table 21: COPD Market - Drivers and Barriers in the US, 2018-2028
Table 22: Key Events Impacting Sales for COPD in the 5EU, 2018-2028
Table 23: COPD Market - Drivers and Barriers in the 5EU, 2018-2028
Table 24: Key Events Impacting Sales for COPD in the Japan, 2018-2028
Table 25: COPD Market - Global Drivers and Barriers in Japan, 2018-2028
Table 26: Historical and projected launch dates for COPD across the 7MM, 2018-2028
Table 27: Historical and projected expiry dates for COPD across the 7MM, 2018-2028
Table 28: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

Figure 1: Global Sales Forecast by Country for COPD in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in COPD for the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to Be Licensed for the Treatment of COPD During the Forecast Period
Figure 4: Normal Lungs and Lungs with COPD
Figure 5: The Pathogenesis of COPD
Figure 6: Refined ABCD Assessment Tool for COPD, 2018
Figure 7: 7MM, Total Prevalence of COPD, Men and Women, Ages =35 Years, 2018
Figure 8: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages =35 Years, 2018
Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
Figure 10: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
Figure 12: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages =35 Years
Figure 13: 7MM, Total Prevalent Cases of COPD, by Sex, Ages =35 Years, 2018
Figure 14: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
Figure 15: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages =35 Years
Figure 16: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages =35 Years, 2018
Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
Figure 18: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages =35 Years, 2018
Figure 19: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages =35 Years, 2018
Figure 20: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages =35 Years, 2018
Figure 21: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages =35 Years, 2018
Figure 22: COPD Treatment Algorithm
Figure 23: Unmet Needs and Opportunities in COPD
Figure 24: Overview of the Development Pipeline in COPD
Figure 25: Key Phase II/III Trials for Promising Pipeline Agents
Figure 26: Competitive Assessment of Late-Stage Pipeline Agents for COPD
Figure 27: Analysis of the Company Portfolio Gap in COPD During the Forecast Period
Figure 28: Global Sales for COPD by Country, 2018 and 2028
Figure 29: Sales for COPD by Drug Class in the US, 2018 and 2028
Figure 30: Sales for COPD by Drug Class in the 5EU, 2018 and 2028
Figure 31: Sales for COPD by Drug Class in Japan, 2018 and 2028